-
1
-
-
84982944216
-
-
National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal. London, NICE 2013 2008
-
National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal. London, NICE 2013 Available at: http://www.nice.org.uk/. 2008.
-
-
-
-
2
-
-
84982944219
-
-
Gilead Sciences Inc. Manufacturer/sponsor submission of evidence for Single Technology Appraisal (STA) of ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]—Company submission. 2014
-
Gilead Sciences Inc. Manufacturer/sponsor submission of evidence for Single Technology Appraisal (STA) of ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]—Company submission. 2014.
-
-
-
-
3
-
-
84982944224
-
Ledipasvir-sofosbuvir for treating chronic hepatitis C: a Single Technology Appraisal
-
Thokala P, Simpson E, Tappenden P, Stevens JW, Dickinson K, Ryder S et al. Ledipasvir-sofosbuvir for treating chronic hepatitis C: a Single Technology Appraisal, School of Health and Related Research (ScHARR), 2015. 2015.
-
(2015)
School of Health and Related Research (ScHARR)
, pp. 2015
-
-
Thokala, P.1
Simpson, E.2
Tappenden, P.3
Stevens, J.W.4
Dickinson, K.5
Ryder, S.6
-
4
-
-
84983019548
-
-
National Institute for Health and Care Excellence, Single Technology Appraisal (STA): ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]. 2015
-
National Institute for Health and Care Excellence, Single Technology Appraisal (STA): ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]. 2015.
-
-
-
-
5
-
-
84983004999
-
European Public Assessment Report—Harvoni
-
European Medicine Agency. European Public Assessment Report—Harvoni. London: EMA; 2014.
-
(2014)
London: EMA
-
-
-
6
-
-
84982877763
-
-
National Institute for Health and Care Excellence, Final appraisal determination ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]. 2015
-
National Institute for Health and Care Excellence, Final appraisal determination ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]. 2015.
-
-
-
-
7
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
-
PID: 24725239
-
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.
-
(2014)
N Engl J Med
, vol.370
, Issue.20
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
Chojkier, M.4
Gitlin, N.5
Puoti, M.6
-
8
-
-
84898669547
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
COI: 1:CAS:528:DC%2BC2cXmvFShtLk%3D, PID: 24725238
-
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.
-
(2014)
N Engl J Med
, vol.370
, Issue.16
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.R.2
Nelson, D.R.3
Lawitz, E.4
Gordon, S.C.5
Schiff, E.6
-
9
-
-
84900326091
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
-
PID: 24720702
-
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.
-
(2014)
N Engl J Med
, vol.370
, Issue.20
, pp. 1879-1888
-
-
Kowdley, K.V.1
Gordon, S.C.2
Reddy, K.R.3
Rossaro, L.4
Bernstein, D.E.5
Lawitz, E.6
-
10
-
-
77950597305
-
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
-
COI: 1:CAS:528:DC%2BC3cXls1Cnt7c%3D, PID: 20069649
-
Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122–6.
-
(2010)
Hepatology
, vol.51
, Issue.4
, pp. 1122-1126
-
-
Martinot-Peignoux, M.1
Stern, C.2
Maylin, S.3
Ripault, M.P.4
Boyer, N.5
Leclere, L.6
-
11
-
-
84877782905
-
Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
-
PID: 23470616
-
Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(7):1450–5.
-
(2013)
Gastroenterology
, vol.144
, Issue.7
, pp. 1450-1455
-
-
Chen, J.1
Florian, J.2
Carter, W.3
Fleischer, R.D.4
Hammerstrom, T.S.5
Jadhav, P.R.6
-
12
-
-
84982896237
-
Hepatitis C (chronic)—sofosbuvir: consultation document. ID654
-
National Instiute for Health and Care Excellence. Hepatitis C (chronic)—sofosbuvir: consultation document. ID654. London: NICE; 2014.
-
(2014)
London: NICE
-
-
-
13
-
-
33746633881
-
-
Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006; 10(21):1–113, iii
-
Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006; 10(21):1–113, iii.
-
-
-
|